Simulations Plus Inc. received an order from China’s drug evaluation agency to license its GastroPlus product.Financial terms of the deal between the Lancaster drug modeling software developer and the Center for Drug Evaluation of the National Medical Products Administration in China were not disclosed.John DiBella, Simulations Plus division president said, the company has cultivated relationships with different institutions affiliated with China’s National Medical Products Administration to use its technology for the evaluation of drug specifications and bioequivalence.“Now, researchers at the CDE will add GastroPlus to serve as a key platform for model-informed drug development to aid regulatory reviews,” DiBella said in a statement. “This news is welcomed by over 20 (and growing) domestic Chinese pharmaceutical companies and research hospitals that have been employing our technologies.”Shares of Simulations Plus (SLP) closed down 27 cents, or a fraction of a percent, to $46.66 on the Nasdaq, on a day when that market closed up a fraction of a percent.